Beyond Air, Inc. (XAIR) Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Beyond Air, Inc. (XAIR) Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

Beyond Air, Inc. (XAIR) Tops Q4 EPS by 2c

June 22, 2020 4:05 PM EDT

Beyond Air, Inc. (NASDAQ: XAIR) reported Q4 EPS of ($0.36), $0.02 better than the analyst estimate of ($0.38).

Recent Highlights and Upcoming Milestones

Announced positive top-line results from the third pilot study in bronchiolitis patients that showed high concentration NO (150 ppm) plus standard supportive therapy (SST) is statistically significant compared to both low concentration nitric oxide (85 ppm) plus SST and SST alone on both the primary endpoint of fit-to-discharge and the key secondary endpoint of hospital length of stay with no serious adverse events related to NO reportedPublished a peer-reviewed paper in the Scientific Reports... More